Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2025-12-31 @ 2:37 PM
Study NCT ID:
NCT04135833
Status:
COMPLETED
Last Update Posted:
2021-04-22
First Post:
2019-10-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000728929', 'term': 'rezivertinib'}, {'id': 'D017964', 'term': 'Itraconazole'}, {'id': 'D012293', 'term': 'Rifampin'}], 'ancestors': [{'id': 'D014230', 'term': 'Triazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D012294', 'term': 'Rifamycins'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D047029', 'term': 'Lactams, Macrocyclic'}, {'id': 'D047028', 'term': 'Macrocyclic Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 31}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-12-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2020-07-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-21', 'studyFirstSubmitDate': '2019-10-21', 'studyFirstSubmitQcDate': '2019-10-21', 'lastUpdatePostDateStruct': {'date': '2021-04-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-10-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-07-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cmax', 'timeFrame': 'Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose', 'description': 'Pharmacokinetics of BPI-7711 by assessment of maximum plasma concentration'}, {'measure': 'AUC(0-last)', 'timeFrame': 'Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose', 'description': 'Pharmacokinetics of BPI-7711 by assessment of area under the plasma concentration time curve from zero to last assessed timepoint'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['NSCLC']}, 'descriptionModule': {'briefSummary': 'This is a phase I study to assess the effect of itraconazole and rifampicin on the pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male, aged from 18 to 45 years\n* BMI from 18.5 to 28.0 kg/m2\n* Medical history, vital signs, physical examination and lab tests are normal or abnormal without clinical significance\n\nExclusion Criteria:\n\n* Subjects with clinical significant diseases\n* Subjects with allergic disease history\n* Subjects with gastrointestinal disease history that can affect study drug absorption\n* Subjects with drug abuse history'}, 'identificationModule': {'nctId': 'NCT04135833', 'briefTitle': 'A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711', 'organization': {'class': 'INDUSTRY', 'fullName': 'Beta Pharma, Inc.'}, 'officialTitle': 'A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 in Chinese Healthy Volunteers', 'orgStudyIdInfo': {'id': 'BPI-7711DDI'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Itraconazole and BPI-7711', 'description': 'BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.', 'interventionNames': ['Drug: BPI-7711', 'Drug: Itraconazole']}, {'type': 'EXPERIMENTAL', 'label': 'Rifampicin and BPI-7711', 'description': 'BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.', 'interventionNames': ['Drug: BPI-7711', 'Drug: Rifampicin']}], 'interventions': [{'name': 'BPI-7711', 'type': 'DRUG', 'otherNames': ['BPI-7711 capsule'], 'description': 'BPI-7711 60 mg', 'armGroupLabels': ['Itraconazole and BPI-7711']}, {'name': 'BPI-7711', 'type': 'DRUG', 'otherNames': ['BPI-7711 capsule'], 'description': 'BPI-7711 180 mg', 'armGroupLabels': ['Rifampicin and BPI-7711']}, {'name': 'Itraconazole', 'type': 'DRUG', 'otherNames': ['Itraconazole capsule'], 'description': 'Itraconazole 200 mg', 'armGroupLabels': ['Itraconazole and BPI-7711']}, {'name': 'Rifampicin', 'type': 'DRUG', 'otherNames': ['Rifampicin capsule'], 'description': 'Rifampicin 600 mg', 'armGroupLabels': ['Rifampicin and BPI-7711']}]}, 'contactsLocationsModule': {'locations': [{'zip': '200000', 'city': 'Shanghai', 'country': 'China', 'facility': 'Shanghai Xuhui Central Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'overallOfficials': [{'name': 'Jingying Jia', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shanghai Xuhui Central Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Beta Pharma, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}